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Aims: The primary aim of the RELAX-OAB study is to confirm the safety and
efficacy of the Axonics r-SNM System, a miniaturized, rechargeable SNM system.
Methods: A total of 51 OAB patients were implanted in a single-stage implant
procedure. These results represent the 3-month outcomes. Subject outcomes were
evaluated using 3-day bladder diaries and quality of life questionnaires.
Results:A total of 31 of 34 patients (91%) that responded during an initial trial period
(“Test Responders”) continued to benefit from therapy with the Axonics r-SNM
System at 3-months, defined as symptom improvement of≥50% reduction in urinary
voids or incontinence episodes or a return to<8voids per day. SubjectswhowereTest
Responders showed a statistically and clinically meaningful improvement in all
aspects of quality of life (ICIQ-OABqol). No serious device-related adverse events
(SADEs) occurred, and there were no unanticipated adverse events (UAEs). One
subject was explanted due to an infection at the implant site and 19.6% of subjects
experienced device related adverse events, most notably discomfort due to
stimulation, which was resolved with reprogramming.
Conclusions: The Axonics r-SNM System provides safe and effective SNM therapy
with objective improvement in 91% of subjects. The data also demonstrates a
significant improvement in all domains of quality of life. This miniaturized,
rechargeable system is designed to last 15 or more years and is expected to provide
clinical and cost benefits over current non-rechargeable systems by eliminating
replacement surgeries.
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1 | INTRODUCTION
Sacral neuromodulation (SNM) is a guideline-recommended
treatment for overactive bladder (OAB) patients with or
without urinary urgency incontinence following failure of
conventional interventions such as life style changes, pelvic
floor exercises, and medications. This therapy has been
shown to significantly reduce symptoms in patients suffering
from refractory urinary urgency and frequency and urgency
incontinence, as well as providing clinically meaningful long-
term improvements in patient quality of life.1,2,3,4
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In 1994, SNM received the CE mark in Europe for the
treatment of chronic functional disorders of the pelvis, lower
urinary tract, and intestinal tract, and in 1997was approved by
the FDA for use in the United States. Over 250 000 patients
have been treated worldwide with SNM since these
approvals.
Currently, SNM therapy is provided using a voltage-
driven, non-rechargeable device (Interstim II®, Med-
tronic, Minneapolis, MN) that typically is replaced every
3–5 years due to battery depletion.5 Device replacement
surgery introduces patient risk and inconvenience as well
as increasing healthcare costs.6,7 Advances in sacral
neuromodulation technology and best practices offer the
potential for providing the long-term benefit of SNM
therapy with reduced need for reoperation. In 2016, the
Axonics r-SNM System™, a miniaturized, rechargeable
SNM system, obtained regulatory approval in Europe and
Canada.
The Axonics r-SNM System (Figure 1) is a miniaturized,
implantable rechargeable SNM (r-SNM) system designed and
tested to deliver therapy in the body for at least 15 years.
The Axonics r-SNM System includes an implantable
neurostimulator that is 5cc in volume, which is over 60%
smaller than the 14cc Interstim II. The neurostimulator
connects to a 4-contact tined lead that is implanted through
the sacral foramen using the same procedure previously
described for other SNM systems.8 The system delivers
constant current stimulation and provides adjustable stimula-
tion parameters appropriate for SNM therapy. Implanted
patients recharge their neurostimulator, expected to be needed
once every 2 weeks, using an external charging unit placed
over the implant. Stimulation parameters are programmed
with a clinician programmer and stimulation intensity is
controlled by the patient using a wireless remote control. An
independent, expert review provides additional detail about
SNM therapy and the characteristics and specifications of the
Axonics r-SNM System.9
The RELAX-OAB study is a prospective, multi-center
post-market clinical follow-up study designed with the
primary aim of confirming the safety and efficacy of the
Axonics r-SNM System as an aid in the treatment of the
symptoms of OAB. The primary hypothesis associated
with the study aim is the mean change in ICIQ-OABqol
HRQL score at 3 months compared to baseline is greater
than zero. The 3-month results detailed in this report are
the first efficacy and safety results reported for treatment
of idiopathic OAB patients with the Axonics r-SNM
System.
2 | MATERIALS AND METHODS
2.1 | Study design
The RELAX-OAB study is a prospective, multi-center, single
arm, open-label study with each subject serving as their own
control. The study is being conducted according to the
stipulations of the Declaration of Helsinki, ISO 14155: 2011
and applicable national regulations. The study protocol was
approved by Ethics Committees at all study sites, and all
subjects gave informed consent prior to participating in the
study. Subjects were eligible for treatment with the Axonics r-
SNM System if they met all inclusion and exclusion criteria
(Table 1).
2.2 | Implant procedure
Subjects underwent a single-stage implant procedure under
general anesthesia. As part of the study design, subjects did
not receive external trial stimulation prior to being implanted,
and had both the tined lead and IPG placed concomitantly.
Fluoroscopic guidance was used to implant the tined lead
along the S3 sacral nerve root. A pocket was made in the
upper buttocks area to accommodate the IPG, and the tined
lead was tunneled subcutaneously to the neurostimulator
pocket. The lead and neurostimulator were connected and
placed in the pocket.
2.3 | Follow-up visits
Study subjects will be followed for 2-years. This report
includes data from follow-up visits at various time points up
to 3 months post-implant, including 2-week and 1-month
visits to assess initial response to therapy. Unscheduled
follow-up visits were allowed as needed to adjust stimulation
settings to optimize therapy. Subjects were considered
therapy responders if they had a ≥50% reduction in urinary
incontinence episodes per day, a ≥50% reduction in voids per
day, or a reduction to <8 voids per day. In the current practice
of sacral neuromodulation, patients are typically screened
with an externalized test stimulation system before proceed-
ing to full implant. In contrast, subjects in this study were
implanted with a full system in a single-stage procedure and
the initial month of stimulation was defined as the test period.
Patients that were therapy responders before their 1-month
FIGURE 1 The Axonics r-SNM System includes a rechargeable,
miniaturized neurostimulator that is 5cc in volume and has a 15-year
approved life in Europe and Canada
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visit were classified as “Test Responders” (Figure 2). The
classification of subjects as Test Responders allows for
comparison with the clinical literature. All subjects continued
to be followed for the duration of the study regardless of test
period response. Therapy response at 3-months was also
evaluated separately for large leaks and severe and desperate
urgency episodes, where response based on these symptoms
was defined as a ≥50% reduction in symptoms. In addition to
the 3-day voiding diary, additional therapy outcomes
included symptom-related quality of life (QOL) surveys
(ICIQ-OABqol, ICIQ-UI Short Form) and patient satisfaction
questionnaires.
2.4 | Adverse events
All adverse events (AEs) were tracked and analyzed to assess
the safety of the Axonics r-SNM System. A Data Safety
Monitoring Board comprised of three expert clinicians not
participating as investigators in the study, reviewed and
adjudicated all adverse events.
2.5 | Statistical analysis
Outcome measures were evaluated based on the implanted
population and based on those subjects that were Test
TABLE 1 Primary study inclusion and exclusion criteria
Inclusion criteria
Diagnosis of OAB as demonstrated on a 3-day voiding diary defined as≥ 8 voids/day, and/or a minimum of two involuntary urinary
incontinence episodes in a 72-h period
Positive motor response on at least two implanted electrodes during intraoperative test
18 years of age or older
Failed, or are not a candidate for more conservative treatment (eg, pelvic floor training, biofeedback, behavioral modification, oral
pharmacotherapy)
No changes to current regimen of medications that affect bladder function for at least 4 weeks prior to beginning the baseline voiding diary
Exclusion criteria
Primary stress incontinence or mixed incontinence where the stress component overrides the urgency component
Current urinary tract mechanical obstruction such as benign prostatic enlargement or urethral stricture
Interstitial cystitis or bladder pain syndrome as defined by either AUA or EAU guidelines
History of any pelvic cancer
Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study
endpoints
Current symptomatic urinary tract infection (UTI) or more than 3 UTIs in past year
Any neurological condition that may interfere with normal bladder function, including stroke, multiple sclerosis, Parkinson's disease,
clinically significant peripheral neuropathy, or spinal cord injury (eg, paraplegia)
Treatment of urinary symptoms with botulinum toxin therapy in the past 12 months
Treatment of urinary symptoms with tibial nerve stimulation in the past 3 months
Previously implanted with a sacral neuromodulation device or participated in a sacral neuromodulation trial
FIGURE 2 Study design. All subjects were implanted with a permanent SNM system without screening with an external trial system. Subjects
were classified based on their response to therapy during the first month post-implant. Subjects that responded to therapy on their qualifying
symptoms (UI: ≥50% reduction in leaks; UF: ≥50% reduction in voids or <8 voids per day) were classified as Test Responders, and non-responders
were classified as Test Failures. All subjects continued to be followed for the duration of the study regardless of test period response
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Responders. Data analysis included therapy responder rates
as well as the absolute change and percent change for the
number of voids, number of incontinence episodes, number of
large incontinence episodes, number of severe and desperate
urgency episodes, and the outcomes of the quality of life
questionnaires. Descriptive statistics were calculated. Statis-
tical significance testing was performed using a two-sided
paired t-test or Wilxocon signed rank test for continuous
variables, and Fisher's exact t-test for categorical variables.
The software package SAS (version 9.3, SAS Institute, Cary,
NC) was used for all analyses.
3 | RESULTS
3.1 | Subject overview
Fifty-one (51) subjects were implanted with the Axonics r-
SNM System at 7 European centers. Baseline characteristics
for all implanted subjects are reported on Table 2. Subjects
were 75% female and 25% male, with a median age of
52 years (range 21-77 years). In addition to conservative
therapy, 51% of subjects had previously tried at least one other
third line OAB therapy, with Botox treatment for 25% and
tibial nerve stimulation for 31% of subjects. Additionally,
20% of subjects previously had sling procedures to treat stress
urinary incontinence. On their baseline diary, 50 of 51
subjects qualified as urgency frequency (UF) subjects and 37
of 51 qualified as urinary urgency incontinence (UI) subjects.
At baseline, implanted UF subjects averaged 14.7 voids per
day (±6.0 SD, n= 50) and UI subjects averaged 9.6
incontinence episodes per day (±5.1 SD, n= 37).
Fifty-one subjects were implanted, and 48 reached 3-months
post-implant without complication or major protocol deviation.
Three patients are excluded from the following analyses—two
subjects due tomajor protocol deviations andone subject thatwas
explanted due to a procedure-related infection.
3.2 | Therapy responders
Thirty-four of 48 per protocol subjects (71%) were Test
Responders during the 1-month test stimulation period. At
3months, 91% of the Test Responders continued to be therapy
responders based on their reductions in leaks and/or voids
(Figure 3A), and 71% of all subjects in the as treated analysis
were therapy responders. For subjects with UUI at baseline,
75% of Test Responders were therapy responders at 3-months
(Figure 3B), including 64% experiencing a≥75% reduction in
leaks per day. A total of 25% of Test Responders were
completely dry at 3-months. The overall UUI response rate
was 64% for all subjects. Further, 89% of all UUI subjects
experienced a >50% reduction in their large leaks. For
subjects with UF at baseline, 73% of Test Responders
continued to respond at 3-months (Figure 3C), including 61%
of Test Responders that achieved normal voiding (<8 voids
per day). The overall UF response rate was 53% for all
subjects, while 70% of all subjects experienced a >50%
reduction in severe and desperate urgency episodes.
3.3 | Diary symptoms
The average number of voids in Test Responder subjects
decreased by 6.6 voids per day at 3-months compared to
baseline (Figure 4A). At 3-months, the average number of
voids was 7.7 voids per day (±0.3, n= 33) compared to 14.3
voids per day (±1.1) at baseline.
Incontinence episodes in Test Responders decreased from
an average of 8.3 per day at baseline (±0.8, n= 28) to 2.0 per
day at 3-months (±0.5, n= 28), an average decrease of 6.3
leaks per day (Figure 4B). A significant decrease of 5.9 leaks
per day was experienced across all subjects between baseline
and 3-months.
3.4 | Quality of life
The mean change in the health related quality of life (HRQL)
total score for the ICIQ-OABqol at 3 month for subjects who
were Test Responders was 27.3 (±3.6 SE; N= 34,
P< 0.0001) (Figure 5), an improvement substantially larger
than the clinically minimally important difference of 10
points, which has previously been used to evaluate SNM
therapy impact on quality of life.2,8 All subscale scores had
clinically meaningful improvements, indicating that r-SNM
TABLE 2 Baseline subject characteristics
n % (n/51)
Gender
Female 38 75%
Male 13 25%
Age Years
Mean (Range) 51 (21–77)
Primary diagnosis
Urgency frequency 27 53%
Urinary urge incontinence 24 47%
Secondary diagnosis
Urgency frequency 12 24%
Urinary urge incontinence 10 20%
Stress incontinence 8 16%
Fecal incontinence 5 10%
OAB qualification in baseline diary
Both UF and UUI 36 71%
UF only 14 27%
UUI only 1 2%
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has a positive impact on all aspects of quality of life. 76% of
Test Responders and 66% of all subjects indicated improved
or greatly improved symptom interference scores. Quality of
life scores all improved across all subjects, with a clinically
meaningful increase in the HRQL total score of 21.8 points
and clinically meaningful increases (>10 points) in all
subscales. Additional quality of life measures provided
similar results as the ICIQ-OABqol. Subjects experienced
clinically and statistically significant improvements in ICIQ-
UI Short Form composite scores, which improved from 14.5
FIGURE 3 r-SNM therapy responder rate at 3-months. (A) OAB symptom response was assessed by evaluating if subjects had a ≥50%
reduction in voids, a ≥50% reduction in all leaks, or a reduction to less than 8 voids per day (n= 48 subjects). (B) UUI responders shown for
two responder criteria: (left) a ≥50% reduction in leaks per day (n= 36 UUI subjects) and (right) a ≥50% reduction in large leaks per day (n= 26
subjects with at least one large leak at baseline). (C) UF responders shown for two responder criteria: (left) a ≥50% reduction in voids per day or
<8 voids per day (n= 47 UF subjects) and (right) a ≥50% reduction in severe and desperate urgency episodes per day (n= 32 subjects with at
least one severe or desperate urgency episode at baseline)
FIGURE 4 Reduction in leaks and voids at 3-months. Average symptoms per day at baseline and 3-months across all subjects and Test
Responders are shown for (A) All leaks (n= 37 all subjects, n= 28 Test Responders) (B) Large leaks (n= 27 all subjects, n= 21 Test
Responders), (C) Voids (n= 47 all subjects, n= 33 Test Responders) and (D) severe and desperate urgency episodes (n= 46 all subjects, n= 32
Test Responders). *,**P< 0.0001 for all comparisons of 3-month symptoms to baseline
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(±3.44) at baseline to 7.32 (±5.4, n= 28, P< 0.0001) at 3-
months for Test Responders. Subjects also reported satisfac-
tion with r-SNM therapy. A total of 82% of Test Responders
and 77% of all subjects were moderately or very satisfied with
r-SNM therapy at 3-months, and 82% of Test Responders and
73% of all subjects would “definitely” recommend r-SNM
therapy to a friend.
3.5 | Adverse events
Across all 51 implanted patients, no unanticipated adverse
device effects occurred within the 3-month post-implant
period, and there were no serious adverse device effects.
Eleven adverse events related to the therapy were reported
across 10 subjects (19.6% of subjects). Six of the 11 events
(55%) occurred within 2 weeks of implant. The most frequent
adverse events were associated with undesirable stimulation,
accounting for five events in four subjects (7.8% of subjects).
These adverse events were resolved with device reprogram-
ming. No surgical intervention was required due to device or
therapy-related adverse events. One serious procedure-
related adverse event occurred, an implant site infection,
and the patient had the system explanted. No other patients,
including Test Non-Responders, were explanted by the 3-
month visit. There were no reported adverse events occurred
related to the recharging of the neurostimulator.
4 | DISCUSSION
The 3-months results of this prospective, multicenter study
demonstrate that the Axonics r-SNM System is a safe and
effective therapy to treat refractory idiopathic overactive
bladder with significant improvement in both objective
voiding diary parameters and subjective quality of life
benefits to the patients. Seventy-one percentage of subjects
responded during an initial test period (“Test Responders”),
and 91% of these subjects continued to be therapy responders
at 3-months. These outcomes are consistent with those
previously reported for the Medtronic Interstim® System.1–4
Additionally, the high rate of patient satisfaction and
likelihood of recommending the therapy to a friend suggests
that at 3-months charging the device does not present a burden
to patients relative to the benefit of their therapy.
To date in the RELAX-OAB study there have been no
unanticipated adverse events and no serious device-related
adverse events. The nature of the reported device related adverse
events is similar to those reported for implanted patients in the
InSite study.2 Undesirable stimulation was the most common
therapy or device-related adverse event in the InSite study and in
this study.This typeof event occurredwithin 3-months of implant
in 6.6% of patients in the InSite study2 and in 7.8% of subjects to
date in this single-stage implant study. In both studies these events
were most often resolved with reprogramming. Overall, these
results show the implant and short-term operation of the Axonics
r-SNM System is safe. Longer-term follow-up is needed to
determine if theAxonics r-SNMSystemimpacts surgical revision
rates and explant rates.
This study implanted the Axonics r-SNM System in a
single-stage procedure without an external trial period.
Subjects were assessed at 2-weeks and 1-month post-implant
to determine if they were responding to SNM therapy,
consistent with the process for evaluating the trial period in
patients screened with a tined lead and external test stimulator
prior to full SNM system implant. For the 71% of subjects that
are responders at 1-month (Test Responders) in this study, a
second surgery would have been required for the implantation
of the neurostimulator had these patients underwent an external
trial period. Nikolavsky et al has shown that a single-stage
implant will provide better patient outcomes while reducing
costs to the healthcare system.11 In addition, a single-stage
procedure decreases the operative burden on surgeons and
patients. Further examination of the data from the subjects that
did not qualify as Test Responders is needed to determine if
these subjects experienced clinically meaningful changes in
symptoms and quality of life at a later time-point. There is
limited literature supporting an ideal trial period duration,
however a few studies suggest longer duration trials (>14days)
may increase the therapy responder rate.12,13
The cost-benefit of rechargeable neuromodulation systems
has been reported for SNM7 and for spinal cord stimulation
systems.14 In both studies, the rechargeable device unsurprisingly
reduced costs due to elimination of device replacement and
associated AEs in patients experiencing long-term success. The
rechargeable SNM device, modeled with a 10-year life, was
projected to save the United States healthcare system $12 billion
FIGURE 5 Quality of Life (ICIQ-OABqol) at Baseline and
3-months in Test Responder subjects. HRQL total and subscale scores
at baseline and 3-month show significant improvements compared to
baseline (*P< 0.0001 for all comparisons, n= 34). Error bars are
standard error. All changes exceed the minimally important difference
(MID, smallest score change typically considered clinically
meaningful to patients) for improvement in quality of life2,10
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over a 15-year period.7 Non-rechargeable SNM therapy has been
shown to be a cost-effective long-term treatment of OAB in
Europe andCanada, including studies showing that SNM ismore
cost-effective than other third line OAB therapies.6,15–19 The
rechargeable Axonics r-SNM System is designed to have a 15-
year life. This rechargeable SNMsystemmay further enhance the
cost-superiority of SNM compared to Botox6,15–19 and percuta-
neous tibial nerve stimulation.6 The long-term follow-up of this
study will provide data to assess the cost implications of the
system and validate the longevity of the device as well as provide
insights into patient preference for a rechargeable system.
However, rechargeable neuromodulation systems (eg, spinal cord
stimulation systems, deep brain stimulation systems) have been
studiedextensively, andpatients haveexperiencedminimal issues
related to charging and are highly satisfied with rechargeable
systems, with 85–90% of patients preferring or recommending
rechargeable devices.20–22
SNM has been shown to effectively treat additional
indications, including fecal incontinence and non-obstructive
urinary retention.23–25 Given the safety and efficacy exhibited
in this study, it is expected that the Axonics r-SNM System
will provide similar safety and efficacy for these indications.
5 | CONCLUSION
The results of this clinical study demonstrate that sacral
neuromodulation with the Axonics r-SNM System is safe and
effective, providing significant improvements in OAB patients'
symptoms as well as all domains of quality of life. Sacral
neuromodulation is a minimally invasive therapy for treating
overactive bladder that has been shown to have superior long-
term efficacy and cost-effectiveness compared to other
treatment options for OAB, and this new rechargeable system
may further improve the cost-effectiveness of SNM therapy.
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